We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
Company Details
- Employees
- 20
- Founded
- -
- Address
- 7 Times Square,
- Phone
- 212-710-9686
- in****@****ife.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://sellaslifesciences.com/
- HQ
- New York, NY
Sellas Life Sciences Group, Inc. Questions
Sellas Life Sciences Group, Inc.'s helpline number is 212-710-9686
Sellas Life Sciences Group, Inc.'s website is https://sellaslifesciences.com/
Sellas Life Sciences Group, Inc.'s LinkedIn profile is https://www.linkedin.com/company/sellas-life-sciences
Sellas Life Sciences Group, Inc. has
20 employees.
View email and phone details for 20
employees at Sellas Life Sciences Group, Inc..
Sellas Life Sciences Group, Inc.'s industry is
Biotechnology Research
Sellas Life Sciences Group, Inc.'s top competitors are
Ocugen,
Jade Biosciences,
Sellas Life Sciences Group Ag,
Synox Therapeutics,
Spear Bio,
Syndax Pharmaceuticals,
Cleara Biotech B.v.,
Pinetree Therapeutics Inc,
Ltz Therapeutics,
Airna.
Sellas Life Sciences Group, Inc.'s support email address is info@sellaslife.com
Sellas Life Sciences Group, Inc.'s categories are Biotechnology Research
Sellas Life Sciences Group, Inc.'s founding year is 2012
